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Abstract
Background: The American Urological Association (AUA) changed their Prostate-Specific Antigen (PSA) screening
guidelines in 2013 to not recommend testing in men under 55 years of age without significant risk factors (such
as a family history of prostate cancer or African ethnicity). The AUA argues that the rates of 'insignificant' prostate
cancer (PC) in men under 55 are so high that the potential harms of PSA-testing in this population (over diagnosis
and overtreatment) outweigh the benefits (early detection and treatment). Our study aims to identify and compare
the rates of insignificant and high-risk PC in men diagnosed with PC ≤55 years and >55 years in two centres in
Sydney, Australia.
Methods: Men with an abnormal screening PSA or DRE and diagnosed with PC by prostate biopsy were included
in this study. A consecutive series of men were accrued from two major urology centres between the years 2006
and 2014. The analysis was divided into two parts, the first compared PC biopsy characteristics between men aged
≤55 years and those >55 years. The second analysis compared the prostatectomy pathological characteristics
between the two groups. Differences were analysed by Chi squared and significance set at p < 0.05.
Results: A total of 598 prostate biopsies and 723 prostatectomy matched subjects were included. On prostate
biopsies, 14.0 % of men ≤55 years and 11.9 % of men >55 years had insignificant PC (X2 = 0.32, df = 1, p = 0.57),
whilst 24.7 % of men ≤55 years and 25.1 % of men >55 years had high-risk PC (X2 = 0.007, df = 1, p = 0.93). On
prostatectomy specimens, 9.1 % of men ≤55 years and 6.5 % of men >55 years had insignificant PC (X2 = 1.25,
df = 1, p = 0.26), whilst 20.0 % of men ≤55 years and 24.0 % of men >55 years had high-risk PC (X2 = 0.83,
df = 1, p = 0.36).
Conclusion: We found no significant difference in the rates of insignificant and high-risk PC between men ≤55 years
and >55 years, in either the prostate biopsies or prostatectomy specimens. Further trials need to be performed with
comparable sample sizes and controlling of risk factors to assess the utility of PSA screening in younger men.
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Background
Prostate Specific Antigen (PSA) testing remains controver-
sial with a diverse range of recommendations on whom to
offer testing to amongst authorities worldwide [1]. In 2013,
the American Urological Association (AUA) changed their
PSA testing guidelines to not recommend testing in men
under 55 years of age without significant risk factors (such
as a family history of prostate cancer or African ethnicity)
[2]. This is in contrast to the 2009 AUA guidelines that
recommended PSA screening start at 40 years. The
AUA argues that the rates of ‘insignificant’ prostate
cancer in men under 55 are so high that the potential
harms of PSA-testing in this population (over diagnosis
and overtreatment) outweigh the benefits (early detection
and treatment). The concept of insignificant prostate
cancer is evolving but generally refers to a low grade,
small volume, organ confined prostate cancer that is
unlikely to manifest clinically in a patient’s lifetime
without treatment [3].
Furthermore, the AUA cites a lack of high-quality evi-
dence to support PSA screening in men 40–55 years.
Specifically, two recently performed large randomized
clinical trials– the Prostate, Lung, Colorectal and Ovarian
Cancer screening trial (PLCO) and European Randomised
Study of Screening for Prostate Cancer (ERSPC) did not
include men under 55 years and therefore do not inform
the decision [4, 5].
In light of the AUA guideline changes, we aim to iden-
tify the rates of insignificant and high-risk prostate cancer
in men diagnosed with prostate cancer in two centres in
Sydney, Australia. In contrast to the AUA, we hypothesise
that there is no significant difference between the rates of
insignificant and high-risk cancer between men ≤55 years
and >55 years.
Methods
Between January 2006 and February 2014 men with an
abnormal screening PSA or DRE subsequently diagnosed
with PC by prostate needle biopsy were included in
this study. A consecutive series of patients were derived
from three surgeons at Westmead hospital (Sydney,
Australia) and one surgeon at St George hospital (Sydney,
Australia). Patient data was de-identified and hence indi-
vidual patient consent was not required for inclusion in
the study. Data collected included patient age, pre-biopsy
PSA score and clinical staging - obtained from audit
databases maintained by each urologist in the study.
Prostate biopsy data (age at biopsy, Gleason score,
number of positive cores, tumour volume, PSA density)
and radical prostatectomy data (age at prostatectomy,
Gleason score, tumour volume, pathological staging) was
obtained via histopathology reports stored on electronic
databases at Douglass Hanley Moir (DHM) – a pathology
company, all four surgeons use exclusively for reporting.
African-American/Australian-African patients were ex-
cluded from the study since this is a known prostate
cancer risk factor.
At DHM, radical prostatectomy specimens are fully
processed but not whole mounted. They are embedded
using standard cassettes, with each slide of the prostate
fully embedded as quadrants in four separate cassettes.
As such, all of the tissue is processed and examined. All
of the tumour areas are drawn on a schematic and the
diagram is used to calculate tumour volume, Gleason
score and presence of extraprostatic extension.
The initial analysis compared PC biopsy characteristics
between men ≤55 years and those >55 years at time of
biopsy. From the prostate biopsy data, subjects were
identified as having insignificant prostate cancer as per
the Epstein criteria [6] (PSA density <0.15 ng/ml per gram,
no Gleason pattern 4 / 5, <3 positives cores and <50 % in-
volvement per core) or high-risk prostate cancer as per
the D’Amico risk grouping [7] (at least one of Gleason
score >7, PSA >20, Clinical stage > T2b). Whilst the
Epstein biopsy criteria is controversial – with some ad-
vocating modifications such as including the presence of
perineural invasion to increase criteria accuracy - it is still
the most commonly used criteria for insignificant prostate
cancer and hence included in this study [6].
The second analysis compared PC characteristics from
prostatectomy specimens between men aged ≤55 years
and those >55 years. This analysis is more robust in
terms of actual pathological cancer differences but sub-
ject to selection bias as some men with low risk cancers
may not have had curative treatment and older men may
be more likely to have radiotherapy rather then surgery.
Similarly, from the prostatectomy data subjects were
identified as having insignificant prostate cancer as
per the Stamey criteria [8] (tumour volume <0.5 cm3,
no Gleason pattern 4 or 5, and no extracapsular spread)
or high-risk prostate cancer as per the D’Amico risk
grouping.
The statistics package SPSS version 21 was used to
perform Chi-square analyses for categorical and dichot-
omous data, and Student’s t-tests for continuous data.
Significance was set at p < 0.05. Ethics approval was
sought and granted by the Western Sydney Local Health
District Human Research Ethics Committee.
Results
There were 794 prostate biopsy subjects identified for
the study, representing a consecutive series. Of these, the
DHM electronic database had complete information for a
total of 598 prostate biopsy and 723 prostatectomy sub-
jects, which were matched. Missing data was attributed to
procedures being performed prior to routine electronic
uploading of histopathology reports. There were no stored
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hard copies of these missing reports and hence they were
excluded from the study.
Table 1 shows the demographic and clinicopathologic
characteristics of the 598 subjects that underwent prostate
biopsy. As demonstrated, the minority of subjects (15.6 %)
were ≤55 years whilst 84.4 % were >55 years (p < 0.001).
The most frequent pre-biopsy PSA value range was 4.1–
10 for both men ≤55 years (59.1 %) and men > 55 (67.7 %)
(p = 0.11). A Gleason score of 3 + 4 was the most common
for both age groups (41.9 % ≤55 years and 45.7 % >55 years)
(p = 0.50) as was a clinical stage of T1c (69.9 % ≤55 years
and 67.5 % >55 years) (p = 0.65).
Table 2 illustrates the prostate biopsy outcomes by
age. 14.0 % of men ≤55 years and 11.9 % >55 years had
insignificant prostate cancer as per the Epstein criteria,
with no significant difference between the two age groups
(X2 = 0.32, df = 1, p = 0.57). Similarly, there was no sig-
nificant difference between the two age groups in
Gleason score >6 (X2 = 2.3, p = 0.13), Gleason score >7
(X2 = 1.2, p = 0.27), Gleason score as a continuous
variable (t = −1.530, p = 0.13, mean difference = −0.195,
95 % CI of difference = −0.45 to 0.06), high-risk prostate
cancer features (X2 = 0.007, p = 0.93) or pre-biopsy PSA
scores (t = 0.977, p = 0.33, mean difference = 1.45, 95 % CI
of difference = −1.50 to 4.41).
The patient characteristics of the 723 subjects that
underwent prostatectomy were similar in nature to the
prostate biopsy patient characteristics (Table 3). There
were less men ≤55 years (15.2 %) than >55 years
(84.8 %) (p < 0.001), a common pre-biopsy PSA value of
4.1–10 in both men ≤55 years (56.4 %) and >55 years
(65.6 %) (p = 0.06),and a common Gleason score 3 + 4
Table 1 Patient characteristics for prostate biopsy specimens for men ≤55 years compared to men >55 years
Characteristic Age ≤55 years Age >55 years Total Significance
Sample numbers 93 (15.6 %) 505 (84.4 %) 598 (100 %) X2 = 283.9, p < 0.001
Age (years)
-Median 53 64 63
-Range 41–55 56–79 41–79
-Mean 51.9 64.3 62.4
Clinical stage
cT1c 65 (69.9 %) 341 (67.5 %) 406 (67.9 %) X2 = 0.20, p = 0.65
cT2a 10 (10.8 %) 64 (12.7 %) 74 (12.4 %) X2 = 0.27, p = 0.61
cT2b 2 (2.2 %) 25 (5.0 %) 27 (4.5 %) X2 = 1.43, p = 0.23
cT2c 14 (15.1 %) 73 (14.5 %) 87 (14.5 %) X2 = 0.02, p = 0.88
cT3a 0 (0 %) 0 (0 %) 0 (0 %) -
cT3b 0 (0 %) 1 (0.2 %) 1 (0.2 %) X2 = 0.18, p = 0.67
Missing 2 (2.2 %) 1 (0.2 %) 3 (0.5 %) X2 = 6.00, p = 0.01
PSA score (ng/mL)
<3 9 (9.7 %) 43 (8.5 %) 52 (8.7 %) X2 = 0.134, p = 0.72
3–4 12 (12.9 %) 41 (8.1 %) 53 (8.9 %) X2 = 2.23, p = 0.14
4.1–10 55 (59.1 %) 342 (67.7 %) 397 (66.4 %) X2 = 2.59, p = 0.11
10.1–20 14 (15.1 %) 73 (14.5 %) 87 (14.5 %) X2 = 0.23, p = 0.88
>20.1 3 (3.2 %) 6 (1.2 %) 9 (1.5 %) X2 = 2.2, p = 0.14
Gleason score
3 + 3 32 (34.4 %) 135 (26.7 %) 167 (27.9 %) X2 = 2.3, p = 0.13
3 + 4 39 (41.9 %) 231 (45.7 %) 270 (45.2 %) X2 = 0.46, p = 0.50
4 + 3 13 (14.0 %) 69 (13.7 %) 82 (13.7 %) X2 = 0.007, p = 0.94
8 5 (5.4 %) 29 (5.7 %) 34 (5.7 %) X2 = 0.02, p = 0.89
9–10 4 (4.3 %) 41 (8.1 %) 45 (7.5 %) X2 = 1.65, p = 0.20
Biopsy
No. cores mean 14.3 13.9 13.9 t = 1.17, p = 0.24, Mean difference = 0.48,
95 % CI of difference = −0.33 to 1.30
% of positive cores mean 31 34 34 t = −1.51, p = 0.13, Mean difference = −3.73,
95 % CI of difference = −8.58 to 1.11
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(51.8 % in men ≤55 years, 53.2 % in men >55 years)
(p = 0.79). Additionally, the pathological stage was most
frequently T2 in men ≤55 years (65.5 %) and men
>55 years (59.5 %) (p = 0.24). Most often there was no
seminal vesicle involvement (92.7 % in men ≤55 years,
92.3 % in men >55 years) (p = 0.89) and negative lymph
nodes (62.7 % in men ≤55 years, 62.6 % in men >55 years)
(p = 0.99). When comparing PSA as a continuous variable
for the prostatectomy subjects there was no significant dif-
ference between men ≤55 and men >50 years (t = −0.365,
p = 0.72, mean difference = −0.29, 95 % CI of difference =
−1.86 to 1.28).
The prostatectomy outcomes paralleled the prostate
biopsy outcomes, with similar rates of insignificant prostate
cancer as per the Stamey criteria (9.1 % in men ≤55 years,
6.5 % in men >55 years) and no statistically significant
difference (X2 = 1.25, p = 0.26) (Table 3). Furthermore,
there were similar mean tumour volumes (t = −1.63,
df = 516, p = 0.10, 95 % CI = −1.01 to 0.95), Gleason
score >6 (X2 = 4.23, p = 0.40), Gleason score >7 (X2 =
0.95, p = 0.33), Gleason score as a continuous variable
(t = −2.000, p = 0.05, mean difference = −0.212, 95 % CI
of difference = −0.42 to 0.00), margin positive status
(X2 = 0.40, p = 0.84) and high-risk prostate cancer (X2 =
0.83, p = 0.36). As expected due to prostate hyperplasia with
increasing age, the prostate weights in the men ≤55 years
was significantly less than in men >55 years (t = −5.11,
df = 191.8, p < 0.001, 95 % CI = −11.69 to −5.17). When
pre-operative PSA levels are compared to prostatectomy
tumour volumes, we find that PSA increases as tumour
volume increases (t = 24.993, df = 515, p < 0.001). Also,
men >55 years on average, have a higher PSA (6.83) and
tumour volume (1.83) compared to men ≤55 years (mean
PSA 6.22, mean tumour volume 1.37).
As described in Table 4, there were 27 men ≤50 years
(4.5 %) and 571 men >50 years (95.5 %) who had pros-
tate biopsies. Of these, 2 men ≤50 years (7.4 %) and 71
men >50 years (12.4 %) had insignificant prostate cancer
(Epstein criteria), with no statistically significant differ-
ence between the two age groups (X2 = 0.55, p = 0.46).
Within the prostatectomy subjects there were 32 men
≤50 years (4.4 %) and 691 men >50 years (95.6 %). Of
these, 2 men ≤50 years (1.8 %) and 48 men >50 years
(7.8 %) had insignificant prostate cancer (Stamey cri-
teria) with no significant difference between the younger
and older men (X2 = 0.008, p = 0.93) (Table 5).
When the group of men ≤55 years was subdivided into
men ≤50 and 51–55 years, similar rates of insignificant
prostate cancer were found in both prostate biopsy and
prostatectomy specimens. From the prostate biopsies, 2
men ≤50 years and 11 men 51–55 years had insignificant
prostate cancer (X2 = 1.238, df = 1, p = 0.27). From the
prostatectomy specimens, 2 men ≤50 years and 8 men
51–55 years had insignificant prostate cancer (X2 = 0.437,
df = 1, p = 0.51).
Discussion
Since the introduction of PSA testing, rates of prostate
cancer diagnosis have dramatically increased whilst pros-
tate cancer mortality has fallen [9]. Despite this, a large
Table 2 Prostate biopsy outcomes for men ≤55 years compared to men >55 years
Factor Age ≤55 years Age >55 years Total Significance
Insignificant prostate cancer (Epstein criteria) 13 (14.0 %) 60 (11.9 %) 73 (12.2 %) X2 = 0.32, p = 0.57
Total 93 505 598
Gleason score
>6 61 (65.6 %) 370 (73.3 %) 431 (72.1 %) X2 = 2.3, p = 0.13
>7 9 (9.7 %) 70 (13.9 %) 79 (13.2 %) X2 = 1.2, p = 0.27
Continuous variable Mean = 2.03 Mean = 2.23 t = −1.53
Std dev = 1.05 Std dev = 1.15 p = 0.13
Mean difference = −0.20
95 % CI of difference = −0.45 to 0.06
PSA comparison Mean = 8.55 Mean = 7.10 t = 0.977
Std dev = 14.26 Std dev = 3.98 p = 0.33
Std error mean =1.48 Std error mean =0.18 Mean difference = 1.45
95 % CI of difference = −1.50 to 4.41
High risk PC
GS > 7 9 (12.5 %) 70 (13.9 %) 79 (13.2 %) X2 = 1.2, p = 0.27
PSA > 20 3 (3.2 %) 6 (1.2 %) 9 (1.5 %) X2 = 2.2, p = 0.14
Clinical stage > T2b 14 (15.1 %) 74 (14.7 %) 88 (14.7 %) X2 = 0.03, p = 0.86
At least one feature of high risk PC 23 (24.7 %) 127 (25.1 %) 150 (25.1 %) X2 = 0.007, p = 0.93
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Table 3 Prostatectomy patient characteristics and outcomes for men ≤55 years compared to men >55 years
Characteristic Age ≤55 years Age >55 years Total Significance
Sample numbers 110 (15.2 %) 613 (84.8 %) 723 (100 %) X2 = 349.9, p < 0.001
Age (years)
-Median 53 64 63
-Range 41–55 56–79 41–79
-Mean 52.0 64.2 62.4
PSA score (ng/mL)
<3 11 (10.0 %) 67 (10.9 %) 78 (10.8 %) X2 = 0.08, p = 0.77
3–4 25 (22.7 %) 43 (7.0 %) 68 (9.4 %) X2 = 27.02, p < 0.001
4.1–10 62 (56.4 %) 402 (65.6 %) 464 (64.2 %) X2 = 3.45, p = 0.06
10.1–20 7 (6.4 %) 90 (14.7 %) 94 (13.4 %) X2 = 5.56, p = 0.02
>20.1 4 (3.6 %) 8 (1.3 %) 12 (1.7 %) X2 = 3.11, p = 0.08
Missing 1 (0.9 %) 3 (0.5 %) 4 (0.6 %) X2 = 0.30, p = 0.59
Continuous variable 110 613 723 (t = −0.365, p = 0.72, mean difference = −0.29,
95 % CI of difference = −1.86 to 1.28)
Gleason score
3 + 3 26 (23.6 %) 96 (15.7 %) 122 (16.9 %) X2 = 4.23, p = 0.40
3 + 4 57 (51.8 %) 326 (53.2 %) 383 (53.0 %) X2 = 0.70, p = 0.79
4 + 3 19 (17.3 %) 128 (20.9 %) 147 (20.3 %) X2 = 0.75, p = 0.39
8 3 (2.7 %) 13 (2.1 %) 16 (2.2 %) X2 = 0.16, p = 0.69
9–10 5 (4.5 %) 50 (8.2 %) 55 (7.6 %) X2 = 1.73, p = 0.19
>6 84 (76.4 %) 517 (84.3 %) 601 (83.1 %) X2 = 4.23, p = 0.40
>7 8 (7.3 %) 63 (10.3 %) 71 (9.8 %) X2 = 0.95, p = 0.33
Continuous variable mean = 2.13 mean = 2.34 t = −2.00
Std dev = 0.96 Std dev = 1.04 p = 0.05
Mean difference = −0.212
95 % CI of difference = −0.42 to 0.00
Pathological stage
pT2 72 (65.5 %) 365 (59.5 %) 437 (60.4 %) X2 = 1.36, p = 0.24
pT3a 24 (21.8 %) 167 (27.2 %) 191 (26.4 %) X2 = 1.41, p = 0.24
pT3b 14 (12.7 %) 80 (13.1 %) 94 (13.0 %) X2 = 0.01, p = 0.93
pT4 0 (0 %) 0 (0 %) 0 (0 %) -
Missing 0 (0 %) 1 (0.2 %) 1 (0.1 %) X2 = 0.18, p = 0.67
Prostate weight Mean = 46.40 Mean = 54.83 t = −5.11,
Std dev = 14.86 Std dev = 20.72 df = 191.8,
p < 0.001,
95 % CI = −11.69 to −5.17
Tumour volume
<0.5 21 (19.1 %) 109 (17.8 %) 130 (18.0 %) X2 = 0.11, p = 0.74
0.5-1 23 (20.9 %) 107 (17.5 %) 130 (18.0 %) X2 = 0.75, p = 0.39
1.1-2 17 (15.5 %) 106 (17.3 %) 123 (17.0 %) X2 = 0.22, p = 0.64
2.1+ 13 (11.8 %) 123 (20.1 %) 136 (18.8 %) X2 = 4.15, p = 0.04
Missing 36 (32.7 %) 168 (27.4 %) 204 (28.2 %) X2 = 1.30, p = 0.25
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proportion of those diagnosed with prostate cancer will
have insignificant prostate cancer [10] – many of whom
will have unnecessary treatment and subsequently ex-
perience morbidity and mortality. It is therefore import-
ant to define a population that would optimally benefit
from PSA testing.
We chose to analyse differences in prostate cancer
pathology on biopsy specimens between the age groups
as this avoids selection bias to some extent. There would
be some selection bias in who gets a prostate biopsy
with an abnormal PSA, however we would expect the
bias would favour older men having more significant
cancer as these men would be more likely to avoid/not
be recommended a biopsy at lower PSA levels [11]. We
also studied the differences in prostatectomy specimen
pathology between the age groups because Epstein cri-
teria has inherent inaccuracies in detecting insignificant
cancers [6]. Prostatectomy specimens allow more accur-
ate determination of pathology but are subject to more
selection bias. Again, we would expect the bias would be
toward older men having more significant cancers, as
younger men would elect to have surgery for less signifi-
cant cancers and opt for active surveillance less readily
then older men as a result of different life expectancies
and co-morbidities [12]. In Australia, PSA screening is
performed by the primary care physicians and patients
Table 3 Prostatectomy patient characteristics and outcomes for men ≤55 years compared to men >55 years (Continued)
Mean tumour volume Mean = 1.37 Mean = 1.82 t = −1.628,
Std dev = 1.51 Std dev = 2.34 df = 516,
p = 0.104,
95 % CI = −1.01 to 0.95
Seminal vesicle
Negative 102 (92.7 %) 566 (92.3 %) 668 (92.4 %) X2 = 0.02, p = 0.89
Positive 8 (7.3 %) 47 (7.7 %) 55 (7.6 %)
Lymph nodes
Negative 69 (62.7 %) 384 (62.6 %) 453 (62.7 %) X2 = 0.00, p = 0.99
Positive 4 (3.6 %) 16 (2.2 %) 20 (2.8 %) X2 = 0.37, p = 0.55
Not taken 37 (33.6 %) 213 (29.5 %) 250 (34.6 %) X2 = 0.05, p = 0.82
Insignificant prostate cancer (Stamey criteria) 10 (9.1 %) 40 (6.5 %) 50 (6.9 %) X2 = 1.25, p = 0.26
Missing 10 (9.1 %) 29 (4.7 %) 39 (5.4 %)
Total 110 613 723
Clinical stage
-Organ confined (pT2, N0NX) 72 (65.5 %) 363 (59.3 %) 435 (60.2 %) X2 = 1.47, p = 0.23
-Non-Organ confined (pT3/4, N0-1) 38 (34.5 %) 249 (40.7 %) 287 (39.8 %)
Margin positive 27 (24.5 %) 156 (25.4 %) 183 (25.3 %) X2 = 0.40, p = 0.84
High risk PCa
GS > 7 8 (7.3 %) 63 (10.3 %) 71 (9.8 %) X2 = 0.95, p = 0.33
PSA > 20 4 (3.6 %) 8 (1.3 %) 12 (1.7 %) X2 = 3.11, p = 0.08
Clinical stage > T2b 15 (13.6 %) 89 (14.5 %) 104 (14.4 %) X2 = 0.06, p = 0.81
At least one feature of high risk PCa 22 (20.0 %) 147 (24.0 %) 169 (23.4 %) X2 = 0.83, p = 0.36
Table 4 Prostate biopsy characteristics and outcomes for men ≤50 years compared to men >50 years
Characteristic Age ≤50 years Age >50 years Total Significance
Sample numbers 27 (4.5 %) 571 (95.5 %) 598 (100 %)
Age (years)
-Median 49 63 63
-Range 41–50 51–79 41–79
-Mean 47.9 63.0 62.4
Insignificant prostate cancer (Epstein criteria) 2 (7.4 %) 71 (12.4 %) 73 (12.2 %) X2 = 0.55, df = 1, p = 0.46
Total 27 571 598
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are generally referred to a urologist when the PSA is
above the age specific reference range. We do not have
data on the total number of men screened in each age
group.
In our study population, there was no statistically signifi-
cant difference in the rates of insignificant or high-risk
prostate cancer between men ≤55 years and >55 years on
either the prostate biopsy or prostatectomy specimens.
Therefore, it would seem to follow that men ≤55 years
would benefit from PSA testing by allowing early detec-
tion of significant prostate cancer in the same way as older
men do. This in turn facilitates early treatment and pre-
vents presentation with advanced disease. Early diagnosis
of significant prostate cancer may be particularly import-
ant in men <55 years as high grade and locally advanced
prostate cancer in this younger group may paradoxically
have worse outcomes compared to their older counter-
parts - potentially reflecting differing prostate cancer
biology in this population [13].
There is currently contradictory evidence in the literature
about the benefit of prostate cancer screening in terms of
reducing prostate cancer-specific mortality. The PLCO and
ERSPC trials are often quoted as the most rigorous of
the available studies, though these give conflicting results.
PLCO concluded that there was no significant prostate
cancer-specific mortality benefit (RR 1.15, 95 % CI 0.86 to
1.54) from screening, whilst ERSPC showed a significant
benefit (RR 0.84, 95 % CI 0.73 to 0.95) [1]. Unfortunately,
neither study included men <55 years, therefore do not
reliably contribute to the discussion of PSA screening
in this age group.
Of the trials that included men <55 years, the Goteborg
population-based randomised trial showed a reduction in
metastatic disease and prostate cancer-specific mortality
when screening started at 50 years [14]. The Quebec trial
included men as young as 45 years though has demon-
strated no benefit in prostate-specific mortality with PSA
testing when using an intention-to-treat analysis [15]. A
Cochrane review exploring the prostate cancer-specific
mortality according to the age of participants at screening
identified no significant difference in prostate cancer-
specific mortality regardless of whether the men were
screened from age 45 years (RR 1.01; 95 % CI 0.76–1.33),
50 years (RR 0.93; 95 % CI 0.69–1.27) or 55 years (RR
1.12; 95 % CI 0.92–1.37) [1].
In a retrospective study, Twiss et al. (2005) found that
men under 50 years had similar rates of significant pros-
tate cancer as men over 50 years when analysing radical
retropubic prostatectomy specimens - implying that
there would be utility in PSA testing both populations
[16]. In contrast, Howard et al. (2009) found that pros-
tate cancer screening beginning at 40 years compared to
50 years would prevent less than 1 prostate cancer death
per 1000 men screened [17]. This is due to the fact that
the rate of prostate cancer detection in the younger age
group is lower than older men. Our study has shown
however that when a cancer is detected in this younger
age group, it is no less aggressive.
The role of a baseline PSA test in younger men for
predicting future risk of prostate cancer is also contro-
versial. There is evidence that PSA testing in men in
their 40’s can stratify risk of developing prostate cancer
in the future, particularly if the baseline PSA is in the
highest centiles above the median [18, 19]. This strategy
would allow men with a high-risk PSA to undergo close
monitoring, whilst sparing men with a low-risk PSA
from regular PSA testing.
This raises the question of at which age PSA testing
should actually be implemented. It may be when below a
certain age there is a statistically significant difference
in the rates of insignificant prostate cancer. In our data
set, when the rates of insignificant prostate cancer in
men ≤50 years were compared to those >50 years in
both the prostate biopsy and prostatectomy specimens -
there remained no difference, suggesting that screening
may still be appropriate at this age.
We acknowledge that the definition of insignificant
cancer has not been well defined clinically and validated
and as such is controversial. Factors such as age and
family history and life-expectancy will have to be in-
cluded in any real pathological definition of insignificant
cancer. In the absence of a well-established definition of
Table 5 Prostatectomy characteristics and outcomes for men ≤50 years compared to men >50 years
Characteristic Age ≤50 years Age >50 years Total Significance
Sample numbers 32 (4.4 %) 691 (95.6 %) 723 (100 %)
Age (years)
-Median
-Range 41–50 51–79 41–79
-Mean
Insignificant prostate cancer (Stamey criteria) 2 (1.8 %) 48 (7.8 %) 50 (6.9 %) X2 = 0.008, df = 1, p = 0.93
Missing 3 (2.7 %) 36 (5.9 %) 39 (5.4 %)
Total 110 613 723
Dantanarayana et al. BMC Urology  (2015) 15:124 Page 7 of 8
insignificant cancer, we chose the Epstein criteria for
needle biopsy and Stamey definition for prostatectomy
specimens, as these are the most commonly reported.
Larger studies need to be designed to assess whether
our findings remain consistent, particularly amongst
different geographical/ethnic populations. Future trails
should include men >40 years to more thoroughly as-
sess prostate cancer screening benefits in terms of
prostate cancer-specific mortality. Ideally, there would
be exclusion of subjects with a family history of prostate
cancer- as this is a known prostate cancer risk factor that
alters PSA screening choice. Nevertheless, it is estimated
that only 5–10 % of prostate cancer is related to a positive
family history [20] and this would not explain the similar-
ities in rates of high-risk prostate cancer in men ≤55 and
>55 years in our study.
Limitations of this study include reliance on a third-
party for availability of recorded and collected data.
There were cases of missing subject data that resulted in
the exclusion of some participants. Ideally, there would
be an equal sample size of men ≤55 and >55 years in the
study, however if consecutive subjects are chosen this is
challenging to accomplish as more men >55 years have
PSA testing and prostate biopsies. Screening calculators
such as the Prostate Cancer Prevention Trial (PCPT)
screening calculator may be used for an individualised
assessment of prostate cancer risk.
Conclusions
PSA testing remains controversial and guidelines will
continue to evolve in the coming years. We found no
significant difference in the rates of insignificant and high-
risk prostate cancer between men ≤55 years and >55 years,
in either the prostate biopsies or prostatectomy speci-
mens. The optimal age to begin PSA testing is yet unclear,
however, our findings suggest that it should be less than
55 years. Further trials need to be performed with compar-
able sample sizes and controlling of risk factors to assess
the utility of PSA screening in younger men.
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